HDQ-P1（人乳腺癌细胞）
CBP60376
询 价
HDQP1细胞全景
产品描述
产品数据库
| I. General information | |
| Synonyms: | HDQ-P1 |
| Background: | established in 1995 from a primary ductal infiltrating breast carcinoma of a 50-year-old Caucasian woman; cells are described in the literature to be estrogen- and progesterone-receptor negative, and to possess a point mutation in p53 and a five-fold amplification of MYC |
| Species: | human (Homo sapiens) |
| Tissue: | breast |
| Disease: | breast carcinoma |
| Gender: | N/A |
| Morphology: | epithelial cells growing adherently in monolayers; |
| Growth Mode: | N/A |
| Doubling Time: | ca. 72 hours |
| DNA Profile: | N/A Our Cell Line Authentication Service |
| Culture Medium: |
DMEM+10%FBS HDQ-P1完全培养基，# CBP60376M |
| Cryopreservation medium: | 90%FBS+10%DMSO |
| Mycoplasma: | negative in microbiological culture, RNA hybridization, PCR assays |
| Immunology: | cytokeratin +, cytokeratin-7 +, cytokeratin-8 +, cytokeratin-17 +, cytokeratin-18 +, cytokeratin-19 +, desmin -, endothel -, EpCAM +, GFAP -, neurofilament -, vimentin + |
| Fingerprint: | multiplex PCR of minisatellite markers revealed a unique DNA profile |
| Species: | confirmed as human by cytogenetics |
| Cytogenetics: | human highly-rearranged flat-moded hypertetraploid/hypopentaploid karyotype with 13% polyploidy - 92-107<4n>XX, -X, -X, +1, -3, -3, -3, +5, +5, +5, +6, +7, +7, -8, +10, -13, -13, -14, -15, -15, -16, -16, -17, -17, -18, -18, -18, -19, -19, -20, -20, -21, -21, -22, -22, -22, +28-29mar, add(X)(p2?)x2, add(1)(p36)x2, add(1)(p35), add(1)(q1?2)x2, der(2)t(2;3)(p16;q11), add(5)(p11q3?4)x2, add(5)(q11), der(5)t(5;?;3)(q1;?;p11), der(5)t(5;5)(p1?;q1?4), i(5p), add(6)(p11), add(7)(p14), add(7)(p11)x2, add(7)(q11)x2, add(8)(q21), del(9)(p23), del(9)(p11), i(10p), del(11)(q22), der(12)t(7;12)(q11;q24), add(14)(p11)x2, add(15)(p11), add(16)(p13), add(16)(q23), add(17)(p11), del(17)(p12), add(18)(p11), add(19)(p13), add(19)(q13), del(22)(q12.2) - HDQ-P1 markers |
| Virus | PCR: EBV -, HBV -, HCV -, HIV-1 -, HIV-2 -, HTLV-I/II -, MLV -, SMRV - |
| Comments: | For more information, please contact us (4008-750-250). |
